HypercholesterolemiaPhase 1NCT04197817
A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects
A Phase 1 study testing JS002 in people with Hypercholesterolemia, run by Shanghai Junshi Bioscience Co., Ltd. at 1 site in China.
Trial summary
JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of JS002 in healthy subjects. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypercholesterolemia
- What is being tested?
- JS002
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteChina
- Study dates
- 11 Dec 2017to 14 Aug 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy men or women aged 18 to 45 years old at screening visit;
- Have the ability to read and understand, volunteer to participate in the study, and signed written informed consent.
- The body mass index (BMI) at screening visit was in the range of 18 to 30 kg/m2 (inclusive) and the body weight ≥ 50 kg.
- The sitting blood pressure ≥90/60 mmHg and <140/90 mmHg at screening visit.
- Serum LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L) at screening visit.
- Serum Triglyceride (TG) level < 250 mg/dL (2.8 mmol/L) at screening visit.
- No fertility [female: documented hysterectomy, bilateral oophorectomy, tubal ligation or other female permanent sterilization, or menopause (menopause for more than one year)], or those with fertility are willing to take, during the entire study period, strict and effective contraceptive measures, in addition, female subjects with fertility should have a negative blood/urine pregnancy test at screening visit.
Who cannot join
- Subjects who meet any of the following criteria will be excluded from the study:
- Evolocumab and/or Alirocumab, or other targeted drugs to PCSK9, has been used at any time.
- Any therapeutic or research biological agents has been used during the first 6 months of baseline/random (Day 0).
- Participated in any clinical study within 3 months prior to baseline/random (Day 0).
- Any drug or health supplement that affects blood lipids or lipid metabolism during the first 30 days of baseline/random (Day 0), including but not limited to: Probucol, statins (e.g. Atorvastatin, Rosuvastatin, etc.), cholesterol absorption inhibitors (such as Ezetimibe), bile acid sequestrants (such as Cholestyramine), red yeast and hawthorn preparations, fibrates, high-purity fish oil preparations (or omega-fatty acids ≥ 1000 mg / day) and niacin preparation (nicotinic acid ≥ 50 mg), etc.
- Start a new intense exercise or diet control within 30 days of random (Day 0) or major changes to previous diet and lifestyle (including exercise, smoking and drinking). The following conditions occur before the baseline/random (Day 0) 1 day (ie Day-1) need to be excluded:
Show all 25Show fewer
- Creatine kinase (CK) ≥ 3 times the upper limit of normal (ULN) (Note: related to exercise), or
- Urinary cotinine is positive, or
- Positive alcohol saliva test.
- Previous or concomitant diseases (such as nephrotic syndrome, liver disease, diabetes, hypothyroidism, etc.) or any clinically significant abnormalities found in physical examinations, laboratory tests, and electrocardiograms, which would make the subject unsuitable for this study.
- The medical history or clinical evidence indicates that the subject had severe acute or chronic disease (including not limited to: heart, kidney, nerves, endocrine, blood, immunity, infection, metabolic disorders, etc.), and the disease has not been controlled, which may confuse the outcome of the study or put the subject at risk judged by the investigator, The following situations need to be excluded:
- had major surgery in the last 6 months, or
- has been hospitalized (e.g. infection) in the last 3 months, or
- donated blood or blood loss ≥500 mL in the past 3 months, or
- has used any prescription or over-the-counter drugs in the past 1 month.
- Transplantation History of organs (such as heart, lung, liver, kidney, etc.) Malignant tumors history, except for cervical carcinoma in situ or surgically resected skin cancer (basal cells and squamous epithelial cells) for more than 5 years.
- Drug abuse or alcohol dependence in the past 1 year.
- HIV infection, or HIV antibody positive at screening visit.
- Syphilis infection, or serotonin antibody (TPPA) positive at screening visit.
- Hepatitis B surface antigen (HBsAg) was positive at screening visit.
- Hepatitis C virus (HCV) antibody was positive at screening visit.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal (ULN); alkaline phosphatase and bilirubin ≥ 1.5 times the upper limit of normal (ULN).
- Allergy history to mammalian-derived biological agents, including monoclonal antibodies.
- Women during pregnancy and lactation.
- Any other investigator believes that the subject is not suitable for the study, such as the subject has potential compliance issues, cannot complete all tests and assessments according to the protocol requirements.
Trial locations and contacts
1 site in 1 country.
China1 site
Fuwai Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100020
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Single-dose Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JS002 (Recombinant Humanized Anti-PCSK9 Monoclonal Antibody) Injection in Healthy Subjects.
JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of JS002 in healthy subjects.
In this study, the dose ascending design includes five dose level cohorts (15 mg, 50 mg, 150 mg, 300 mg, and 450 mg) administered by subcutaneous injection, and three intravenous administration cohorts (15 mg, 150 mg, and 450 mg). Each cohort will enroll 8 to 12 subjects (distribution of study drug and placebo in a 3:1 ratio).
The duration of the study is 84-day per subjects.
- Conditions
- Hypercholesterolemia
- Being tested
- JS002, Placebo
- Medical subject headings
- Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JS002Drug
Also called Recombinant humanized Anti- PCSK9 monoclonal antibody
JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
PlaceboDrug
Also called Placebo of Recombinant humanized Anti- PCSK9 monoclonal antibody
Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
| Study group | Role | What they receive |
|---|---|---|
| JS002 | Active comparator | JS002, Subcutaneous or intravenous injection Receives: Drug: JS002 |
| Placebo, | Placebo comparator | Placebo,Subcutaneous or intravenous injection Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with adverse events（SAE, drug-related (S)AE etc）based on physical examinations, vital signs, 12 lead ECGs , laboratory tests and injection site reactions.
Measured: Up to 84 days after dose administration
Secondary outcomes (3)
Number of participants with anti-drug antibodies.
Measured: Up to 84 days after dose administration
Serum concentrations of JS002 at different timepoint after the drug administration.
Measured: Up to 84 days after dose administration
Change from baseline in LDL-C and other lipid parameters (TC, HDL-C, non-HDL-C, VLDL-C, ApoB, ApoA1, Lp(a) and TG).
Measured: Up to 84 days after dose administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2019
- Study start11 Dec 2017
- Primary completion14 Aug 2018
- Study completion14 Aug 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypercholesterolemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04197817
- Sponsor's protocol ID
- JS002-001
- Status last verified
- Dec 2019
- First submitted
- 1 Dec 2019
- Last updated
- 13 Dec 2019
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Single-dose Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JS002 (Recombinant Humanized Anti-PCSK9 Monoclonal Antibody) Injection in Healthy Subjects.
- ClinicalTrials.gov ID
- NCT04197817
- Acronym / sponsor ID
- JS002-001
- Conditions
- Hypercholesterolemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.University, hospital or other
- Study start
- 11 Dec 2017 (actual)
- Primary completion
- 14 Aug 2018 (actual)
- Study completion
- 14 Aug 2018 (actual)
- First posted
- 13 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of JS002 in healthy subjects.
In this study, the dose ascending design includes five dose level cohorts (15 mg, 50 mg, 150 mg, 300 mg, and 450 mg) administered by subcutaneous injection, and three intravenous administration cohorts (15 mg, 150 mg, and 450 mg). Each cohort will enroll 8 to 12 subjects (distribution of study drug and placebo in a 3:1 ratio).
The duration of the study is 84-day per subjects.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| JS002 | Active comparator | Drug: JS002JS002, Subcutaneous or intravenous injection |
| Placebo, | Placebo comparator | Drug: PlaceboPlacebo,Subcutaneous or intravenous injection |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy men or women aged 18 to 45 years old at screening visit;
- Have the ability to read and understand, volunteer to participate in the study, and signed written informed consent.
- The body mass index (BMI) at screening visit was in the range of 18 to 30 kg/m2 (inclusive) and the body weight ≥ 50 kg.
- The sitting blood pressure ≥90/60 mmHg and <140/90 mmHg at screening visit.
- Serum LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L) at screening visit.
Key exclusion criteria (25 listed)
- Subjects who meet any of the following criteria will be excluded from the study:
- Evolocumab and/or Alirocumab, or other targeted drugs to PCSK9, has been used at any time.
- Any therapeutic or research biological agents has been used during the first 6 months of baseline/random (Day 0).
- Participated in any clinical study within 3 months prior to baseline/random (Day 0).
- Any drug or health supplement that affects blood lipids or lipid metabolism during the first 30 days of baseline/random (Day 0), including but not limited to: Probucol, statins (e.g. Atorvastatin, Rosuvastatin, etc.), cholesterol absorption inhibitors (such as Ezetimibe), bile acid sequestrants (such as Cholestyramine), red yeast and hawthorn preparations, fibrates, high-purity fish oil preparations (or omega-fatty acids ≥ 1000 mg / day) and niacin preparation (nicotinic acid ≥ 50 mg), etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JS002Also: Recombinant humanized Anti- PCSK9 monoclonal antibodyJS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design | Drug | JS002 |
| PlaceboAlso: Placebo of Recombinant humanized Anti- PCSK9 monoclonal antibodyPlacebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design | Drug | Placebo, |
Primary outcome
Number of participants with adverse events（SAE, drug-related (S)AE etc）based on physical examinations, vital signs, 12 lead ECGs , laboratory tests and injection site reactions.
Time frame: Up to 84 days after dose administration
3 secondary outcomes
Number of participants with anti-drug antibodies.
Time frame: Up to 84 days after dose administration
Serum concentrations of JS002 at different timepoint after the drug administration.
Time frame: Up to 84 days after dose administration
Change from baseline in LDL-C and other lipid parameters (TC, HDL-C, non-HDL-C, VLDL-C, ApoB, ApoA1, Lp(a) and TG).
Time frame: Up to 84 days after dose administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2019.
Related trials for Hypercholesterolemia
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia
Not yet recruiting
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3
Familial Hypercholesterolemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing JS002 in people with Hypercholesterolemia, run by Shanghai Junshi Bioscience Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with adverse events（SAE, drug-related (S)AE etc）based on physical examinations, vital signs, 12 lead ECGs , laboratory tests and injection site reactions. (time frame: Up to 84 days after dose administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2019.